<DOC>
	<DOCNO>NCT01903330</DOCNO>
	<brief_summary>This phase II clinical trial study well ERC1671 plus Granulocyte-macrophage colony-stimulating factor ( GM-CSF ) plus Cyclophosphamide Bevacizumab work compare Placebo Injection plus Placebo Pill Bevacizumab treat patient recurrent/progressive , bevacizumab naïve glioblastoma multiforme gliosarcoma ( World Health Organization ( WHO ) grade IV malignant glioma , GBM ) .</brief_summary>
	<brief_title>ERC1671/GM-CSF/Cyclophosphamide Treatment Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : The primary objective study determine 6-month progression free survival probability patient recurrent , bevacizumab naïve glioblastoma multiforme treat ERC1671 combination GM-CSF cyclophosphamide plus bevacizumab compare patient receive bevacizumab plus placebo control . SECONDARY OBJECTIVES : 1 . To evaluate radiographic response , progression free survival overall survival patient recurrent malignant glioma treat ERC1671 regimen plus bevacizumab 2 . To evaluate safety tolerability ERC1671 plus bevacizumab among patient recurrent glioblastoma . 3 . To characterize immune response ERC1671 vaccination adult patient relapse glioblastoma . The patient 's immune response evaluation include cytotoxic T lymphocyte ( CTL ) ( cluster differentiation 3+ ( CD3+ ) /cluster differentiation 8+ ( CD8 ) + ) Treg ( cluster differentiation 3+/cluster differentiation 4+ ( CD4+ ) /cluster differentiation 25+ ) CD25+/cluster differentiation 127low ( CD127low ) ) population . Cytokine analyse initially limited interferon ( IFN ) -ɣ , tumor necrosis factor ( TNF ) interleukin ( IL ) -6 ) . Further immune study include TGF-B2 , IL-12 , IL-10 . If study demonstrate combination regimen ERC1671 combination bevacizumab associate encouraging anti-tumor activity among patient recurrent glioblastoma multiforme , assessment regimen phase III study consider . OUTLINE : This blind Phase II study ERC1671 combination bevacizumab patient relapse , bevacizumab naive glioblastoma . The patient randomize ( 1:1 ratio ) receive either ERC 1671 combination GM-CSF cyclophosphamide placebo control , combination bevacizumab . The study double blind . ERC1671/GM-CSF intradermally administer , cyclophosphamide orally administer . GM-CSF dose 250 µg/m² cyclophosphamide dose 50 mg/day . Bevacizumab administer standard care 10 mg/kg . The treatment cycle 28 day long .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Patients must histologically confirm diagnosis recurrent/progressive WHO grade IV malignant glioma ( glioblastoma multiforme gliosarcoma ) meet follow inclusion criterion : Age ≥18 year age . Histologic diagnosis glioblastoma gliosarcoma ( WHO Grade IV ) . Karnofsky performance status ( KPS ) ≥ 70 % . Life expectancy &gt; 12 week . First second relapse glioblastoma . Previous treatment glioblastoma must include surgery ( biopsy , partial resection , full surgical resection ) , conventional radiation therapy temozolomide ( TMZ ) . MRI record must obtain show MRI conduct least 4 week salvage surgery , least 12 week radiation therapy , least 4 week radiation new lesion outside prior primary radiation field . If prior therapy gamma knife focal highdose radiation , must subsequent histologic documentation local relapse , relapse new lesion outside irradiated field . Resolution chemotherapy radiationrelated toxicity ≤ CTCAE Grade 1 severity , except alopecia hematologic toxicity . Patients take temozolomide start study treatment 23 day last temozolamide dose . For chemotherapy drug , study treatment start long adverse event related treatment &lt; /= Grade 1 . Systemic corticosteroid therapy must dose ≤ 4 mg dexamethasone equivalent per day week prior Day 1 . Patients must normal organ marrow function define : hemoglobin ( Hbg ) &gt; 9g/dL , leukocytes &gt; 1,500/microliter ( mcL ) absolute neutrophil count &gt; 1,000/mcL CD4 count &gt; 450/mcL platelet &gt; 125,000/mcL total bilirubin within normal institutional limit aspartate aminotransferase ( AST ) ( SGOT ) / Alanine aminotransferase ( ALT ) ( SGPT ) &lt; 2.5 X institutional upper limit normal serum creatinine &lt; 1.5 mg/dl Signed informed consent approve Institutional Review Board ; If sexually active , patient must agree take contraceptive measure duration treatment . Subjects unable undergo MRI contrast . Presence diffuse leptomeningeal disease History , presence , suspicion metastatic disease Administration immunosuppressive drug le 2 week prior first dose ERC1671 , except dexamethasone cerebral edema detail ; Prior receipt bevacizumab VEGF VEGF receptortargeted agent Known contraindication hypersensitivity component bevacizumab . Evidence recent hemorrhage screen MRI brain follow exception : presence hemosiderin ; resolve hemorrhagic change relate surgery ; presence punctate hemorrhage tumor . Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) recent peripheral arterial thrombosis within 6 month prior Day 1 . Evidence bleed diathesis coagulopathy document elevated PT , PTT bleed time History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 1 . Urine protein : creatinine ratio ≥ 1.0 screening ; Anticipation need major surgical procedure course study . Serious nonhealing wound , ulcer , bone fracture . Active infection require treatment , know immunosuppressive disease , active systemic autoimmune disease lupus , receipt systemic immunosuppressive therapy , human immunodeficiency virus ( HIV ) infection , Hepatitis B Hepatitis C Uncontrolled hypertension , blood pressure &gt; 150 mmHg systolic &gt; 100 mmHg diastolic , history hypertensive encephalopathy . Subjects know uncontrolled intercurrent illness include ongoing active infection , symptomatic congestive heart failure ( NYHA Gr.2 &gt; ) , myocardial infarction , unstable angina pectoris , within past 12 month Stroke , transient ischemic attack , unstable angina , myocardial infarction congestive heart failure ( New York Heart Association Grade II great ) within past 12 month . Unstable severe intercurrent medical condition chronic renal disease , uncontrolled diabetes mellitus . Women pregnant lactating . All female patient reproductive potential must negative pregnancy test prior Day 1 . Men refuse exercise reliable form contraception . History malignancy ( glioblastoma ) last three year except nonmelanoma skin cancer , situ cervical cancer , treat superficial bladder cancer cure , earlystage prostate cancer patient Prostate Surface Antigen ( PSA ) level &lt; ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ERC1671</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>